ES2411604T3 - Compuestos orgánicos - Google Patents

Compuestos orgánicos Download PDF

Info

Publication number
ES2411604T3
ES2411604T3 ES07853119T ES07853119T ES2411604T3 ES 2411604 T3 ES2411604 T3 ES 2411604T3 ES 07853119 T ES07853119 T ES 07853119T ES 07853119 T ES07853119 T ES 07853119T ES 2411604 T3 ES2411604 T3 ES 2411604T3
Authority
ES
Spain
Prior art keywords
alkyl
inhibitor
formula
aryl
pde
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07853119T
Other languages
English (en)
Spanish (es)
Inventor
Sharon Mates
Allen A. FIENBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Application granted granted Critical
Publication of ES2411604T3 publication Critical patent/ES2411604T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES07853119T 2006-11-13 2007-11-13 Compuestos orgánicos Active ES2411604T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85873206P 2006-11-13 2006-11-13
US858732P 2006-11-13
US87317506P 2006-12-05 2006-12-05
US873175P 2006-12-05
PCT/US2007/023854 WO2008063505A1 (en) 2006-11-13 2007-11-13 Organic compounds

Publications (1)

Publication Number Publication Date
ES2411604T3 true ES2411604T3 (es) 2013-07-05

Family

ID=39430011

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07853119T Active ES2411604T3 (es) 2006-11-13 2007-11-13 Compuestos orgánicos

Country Status (5)

Country Link
US (1) US9198924B2 (cg-RX-API-DMAC7.html)
EP (1) EP2081431B1 (cg-RX-API-DMAC7.html)
JP (3) JP2010509399A (cg-RX-API-DMAC7.html)
ES (1) ES2411604T3 (cg-RX-API-DMAC7.html)
WO (1) WO2008063505A1 (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160307A0 (en) 2001-08-31 2004-07-25 Univ Rockefeller Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
EP1888534B1 (en) 2005-06-06 2017-07-26 Intra-Cellular Therapies, Inc. Organic compounds
WO2007025103A2 (en) * 2005-08-23 2007-03-01 Intra-Cellular Therapies, Inc. Organic compounds for treating reduced dopamine receptor signalling activity
US9255099B2 (en) 2006-06-06 2016-02-09 Intra-Cellular Therapies, Inc. Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors
JP2010509399A (ja) 2006-11-13 2010-03-25 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
EP2089034A4 (en) * 2006-12-05 2010-07-28 Intra Cellular Therapies Inc NEW USES
DK2240490T3 (da) 2007-12-06 2013-12-16 Takeda Pharmaceutical Organiske forbindelser
AU2008331833A1 (en) * 2007-12-06 2009-06-11 Intra-Cellular Therapies, Inc Organic compounds
US8927556B2 (en) 2008-12-06 2015-01-06 Intra-Cellular Therapies, Inc. 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds
PE20110922A1 (es) * 2008-12-06 2012-01-22 Intra Cellular Therapies Inc DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1)
SG171777A1 (en) 2008-12-06 2011-07-28 Intra Cellular Therapies Inc Organic compounds
ES2544976T3 (es) * 2008-12-06 2015-09-07 Intra-Cellular Therapies, Inc. Compuestos de 4,5,7,8-tetrahidro-2H-imidazo[1,2-a]pirrolo[3,4-e]pirimidina como inhibidores de la PDE1
BRPI0922131A2 (pt) * 2008-12-06 2015-08-18 Intracellular Therapies Inc Compostos orgânicos
GEP20146029B (en) 2008-12-06 2014-02-10 Intracellular Therapies Inc Organic compounds
JP2012518685A (ja) 2009-02-25 2012-08-16 イントラ−セルラー・セラピーズ・インコーポレイテッド 眼障害のためのｐｄｅ１阻害剤
WO2010132127A1 (en) 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Organic compounds
SG10201507362TA (en) 2009-08-05 2015-10-29 Intra Cellular Therapies Inc Novel Regulatory Proteins And Inhibitors
EP2485771A4 (en) * 2009-10-08 2014-11-12 Intra Cellular Therapies Inc TRACER AND METHODS TAGGED ON PHOSPHODIESTERASE 1
EP2590657A4 (en) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
TW201206937A (en) * 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
EP2956141A4 (en) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc NEW USES
TWI659032B (zh) 2013-03-15 2019-05-11 美商內胞醫療公司 有機化合物及其用途
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
EP3702358A1 (en) 2013-06-21 2020-09-02 Intra-Cellular Therapies, Inc. Process for preparing salts of a known pde1 inhibitor
EP3091983B1 (en) 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
EP3157926B1 (en) 2014-06-20 2019-05-15 Intra-Cellular Therapies, Inc. Organic compounds
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
ES2915200T3 (es) * 2014-09-17 2022-06-21 Intra Cellular Therapies Inc Derivados de 7,8-dihidro-[2H]-imidazo-[1,2-a]pirazolo[4,3-e]pirimidin-4(5H)-ona como inhibidores de fosfodiesterasa 1 (PDE1) para tratar enfermedades, trastornos o lesiones del sistema nervioso central (SNC)
KR102557603B1 (ko) 2014-12-06 2023-07-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
HK1244427A1 (zh) 2014-12-06 2018-08-10 Intra-Cellular Therapies, Inc. 有机化合物
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
WO2021046179A1 (en) 2019-09-03 2021-03-11 Intra-Cellular Therapies, Inc. Novel compounds
WO2021226407A1 (en) 2020-05-06 2021-11-11 Intra-Cellular Therapies, Inc. Free base crystals
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6032638B2 (ja) 1976-09-01 1985-07-29 武田薬品工業株式会社 ３−アミノピラゾロ〔３，４−ｄ〕ピリミジン誘導体
EP0063381A1 (de) 1981-04-22 1982-10-27 Byk Gulden Lomberg Chemische Fabrik GmbH Neue Pyrazolo(3,4-d)pyrimidine, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US4738985A (en) * 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
NZ238609A (en) * 1990-06-21 1993-12-23 Schering Corp Polycyclic guanine derivatives; preparation, pharmaceutical compositions,
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US20020006963A1 (en) 1992-06-23 2002-01-17 Young James W. Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
AU681875B2 (en) 1993-02-26 1997-09-11 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5824683A (en) * 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
EP0946523A1 (en) * 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
WO1998056324A1 (en) * 1997-06-13 1998-12-17 Arthrocare Corporation Electrosurgical systems and methods for recanalization of occluded body lumens
US6013621A (en) * 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
WO1999051582A1 (en) * 1998-03-31 1999-10-14 Kyowa Hakko Kogyo Co., Ltd. Nitrogenous heterocyclic compounds
US6133273A (en) * 1998-05-08 2000-10-17 American Home Products Corporation Pyrazolopyrimidine-2,4-dione sulfonamides
GB9907658D0 (en) * 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
WO2001000213A1 (en) * 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
US6316444B1 (en) * 1999-06-30 2001-11-13 Merck & Co., Inc. SRC kinase inhibitor compounds
DE19931206A1 (de) 1999-07-07 2001-01-11 Stief Christian Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung
PL355639A1 (en) 1999-09-10 2004-05-04 Merck & Co, Inc. Tyrosine kinase inhibitors
CN1377354A (zh) * 1999-09-30 2002-10-30 纽罗杰有限公司 某些亚烷基二胺一取代的吡唑并[1,5－a]－1,5－嘧啶和吡唑并[1,5－a]－1,3,5－三嗪
CZ20021151A3 (cs) * 1999-10-11 2003-03-12 Pfizer Inc. 5-(2-substituovaný-5-heterocyklylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]-pyrimidin-7-ony jako inhibitory fosfodiesterasy
IL152925A (en) * 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CA2407031A1 (en) * 2000-04-19 2001-10-25 Lilly Icos Llc Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6693009B1 (en) * 2000-11-15 2004-02-17 Advanced Micro Devices, Inc. Flash memory cell with minimized floating gate to drain/source overlap for minimizing charge leakage
US7078016B2 (en) 2001-11-21 2006-07-18 Alexza Pharmaceuticals, Inc. Delivery of caffeine through an inhalation route
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
AU2002324666B2 (en) * 2001-08-10 2007-10-11 The Rockefeller University Compostions and methods for modulation of DARPP-32 phosphorylation
DE60226615D1 (cg-RX-API-DMAC7.html) 2001-08-28 2008-06-26 Schering Corp
IL160307A0 (en) * 2001-08-31 2004-07-25 Univ Rockefeller Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
US6649908B2 (en) * 2001-09-20 2003-11-18 Agilent Technologies, Inc. Multiplexing capillary array for atmospheric pressure ionization-mass spectrometry
CA2465893A1 (en) 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
US7579324B2 (en) * 2002-02-15 2009-08-25 C-A-I-R Biosciences Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
EP1476200A4 (en) * 2002-02-21 2008-08-13 Univ Rockefeller COMPOSITION AND METHOD FOR REGULATING CALCIUM DEPENDENT SIGNALING IN THE BRAIN
SE0203825D0 (sv) 2002-12-20 2002-12-20 Astrazeneca Ab Novel fused heterocycles and uses thereof
AU2004226353A1 (en) * 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
EP1888534B1 (en) 2005-06-06 2017-07-26 Intra-Cellular Therapies, Inc. Organic compounds
WO2007025103A2 (en) 2005-08-23 2007-03-01 Intra-Cellular Therapies, Inc. Organic compounds for treating reduced dopamine receptor signalling activity
US9255099B2 (en) * 2006-06-06 2016-02-09 Intra-Cellular Therapies, Inc. Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors
JP2010509399A (ja) 2006-11-13 2010-03-25 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
EP2089034A4 (en) * 2006-12-05 2010-07-28 Intra Cellular Therapies Inc NEW USES
AU2008331833A1 (en) 2007-12-06 2009-06-11 Intra-Cellular Therapies, Inc Organic compounds
DK2240490T3 (da) 2007-12-06 2013-12-16 Takeda Pharmaceutical Organiske forbindelser
PE20110922A1 (es) * 2008-12-06 2012-01-22 Intra Cellular Therapies Inc DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1)
SG171777A1 (en) * 2008-12-06 2011-07-28 Intra Cellular Therapies Inc Organic compounds
BRPI0922131A2 (pt) * 2008-12-06 2015-08-18 Intracellular Therapies Inc Compostos orgânicos
GEP20146029B (en) * 2008-12-06 2014-02-10 Intracellular Therapies Inc Organic compounds
US8927556B2 (en) * 2008-12-06 2015-01-06 Intra-Cellular Therapies, Inc. 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds
ES2544976T3 (es) * 2008-12-06 2015-09-07 Intra-Cellular Therapies, Inc. Compuestos de 4,5,7,8-tetrahidro-2H-imidazo[1,2-a]pirrolo[3,4-e]pirimidina como inhibidores de la PDE1
JP2012518685A (ja) * 2009-02-25 2012-08-16 イントラ−セルラー・セラピーズ・インコーポレイテッド 眼障害のためのｐｄｅ１阻害剤
WO2010132127A1 (en) * 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Organic compounds

Also Published As

Publication number Publication date
US20100087450A1 (en) 2010-04-08
WO2008063505A1 (en) 2008-05-29
EP2081431A1 (en) 2009-07-29
EP2081431B1 (en) 2013-01-16
US9198924B2 (en) 2015-12-01
EP2081431A4 (en) 2011-01-19
JP2010509399A (ja) 2010-03-25
JP6360025B2 (ja) 2018-07-18
JP2014012662A (ja) 2014-01-23
JP2016104723A (ja) 2016-06-09

Similar Documents

Publication Publication Date Title
ES2411604T3 (es) Compuestos orgánicos
ES2645371T3 (es) Compuestos orgánicos
JP6038250B2 (ja) 有機化合物
ES2638912T3 (es) Compuestos orgánicos
ES2544976T3 (es) Compuestos de 4,5,7,8-tetrahidro-2H-imidazo[1,2-a]pirrolo[3,4-e]pirimidina como inhibidores de la PDE1
ES2836129T3 (es) Compuestos orgánicos
ES2551133T3 (es) Compuestos de 4,5,7,8-tetrahidro-4-oxo-2H-imidazo[1,2-a]pirrolo[3,4-e]pirimidina como inhibidores de PDE1
ES2626006T3 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como inhibidores de PDE9A
US9849132B2 (en) Products and pharmaceutical compositions
WO2007025103A2 (en) Organic compounds for treating reduced dopamine receptor signalling activity
JP2013231074A (ja) 新規使用
EP3509589A1 (en) Novel uses
EP4017858A1 (en) Organic compounds
WO2021127517A1 (en) Novel uses
BR112015023592B1 (pt) Compostos orgânicos inibidores de pde1, composição farmacêutica que compreende os mesmos e uso terapêutico dos ditos compostos e da dita composição
HK1113272B (en) Organic compounds
HK1113272A (en) Organic compounds